IDDF2019-ABS-0188 Gut microbiota modulates the chemopreventive efficacy of aspirin on colorectal cancer through impact on aspirin bioavailability

Risheng Zhao, Olabisi Oluwabukola Coker, Jian‐Lin Wu, Liuyang Zhao, Geicho Nakatsu, Xiqing Bian, Joseph J.�y. Sung, Francis K.l. Chan, Emad El‐Omar2019 · DOI

Introduction

Aspirin is widely recognized as a potent chemopreventive agent, particularly in reducing the incidence and mortality of colorectal cancer (CRC). However, clinical outcomes have been notoriously inconsistent across different patient populations. While the gut microbiota is known to be a pivotal regulator in CRC development and a significant player in drug metabolism, its specific role in aspirin-mediated prevention has remained unclear. This study investigates whether the gut microbiome acts as a metabolic barrier, deactivating aspirin before it can exert its protective effects.

Methodology

To decipher the relationship between the microbiome and aspirin efficacy, researchers utilized two distinct mouse models of colorectal cancer: the azoxymethane/dextran sulfate sodium (AOM/DSS) chemically induced model and the $APC^{min/+}$ genetic model.

The study compared three groups of mice:

  1. Microbiota-intact mice: Conventionally reared mice with a standard gut microbiome.
  2. Microbiota-depleted mice: Mice treated with a broad-spectrum antibiotic cocktail (vancomycin, ampicillin, metronidazole, and neomycin).
  3. Germ-free (GF) mice: Mice raised in a sterile environment, lacking any microbiota.

Aspirin was administered orally (400 mg/L). The researchers used Ultra-High Performance Liquid Chromatography (UHPLC) to measure aspirin concentrations in plasma and culture media. To identify specific aspirin-degrading bacteria, they screened 1,093 bacterial colonies isolated from mouse feces using 16S rRNA gene sequencing and validated findings through monocolonization experiments in germ-free mice.

Key Findings

The Microbiome Impairs Aspirin Efficacy

The most significant finding was that aspirin’s ability to reduce tumor load was contingent on the state of the gut microbiota. In both the AOM/DSS and $APC^{min/+}$ models, aspirin significantly reduced tumor number and load in antibiotic-treated and germ-free mice. Conversely, in mice with an intact microbiome, aspirin treatment failed to produce a significant reduction in tumor metrics. This suggests that the presence of certain gut bacteria actively interferes with aspirin’s chemopreventive function.

Impact on Systemic Bioavailability

UHPLC analysis revealed the mechanism behind this interference: bioavailability. Plasma levels of aspirin were significantly higher in microbiota-depleted and germ-free mice compared to those with intact microbiomes. Furthermore, when aspirin was co-incubated with fecal commensal bacteria from microbiota-intact mice, the drug levels in the medium were rapidly reduced. This confirmed that the gut microbiota limits the amount of aspirin that reaches the bloodstream by degrading it within the gastrointestinal tract.

Identification of Lysinibacillus sphaericus

Through systematic screening of over a thousand bacterial isolates, the researchers identified Lysinibacillus sphaericus as a primary culprit. This specific bacterium was shown to significantly reduce aspirin levels in vitro. To confirm its role in vivo, germ-free mice were monocolonized with L. sphaericus. These mice exhibited significantly lower plasma aspirin levels following oral administration compared to sterile germ-free mice, proving that this single species is sufficient to reduce aspirin bioavailability.

Discussion and Implications

This research highlights a critical, previously overlooked factor in cancer prevention: the microbial metabolism of drugs. The discovery that L. sphaericus (and potentially other species) can degrade aspirin suggests that a "one-size-fits-all" approach to aspirin dosing for CRC prevention may be ineffective.

Precision Prevention

The study opens the door for "precision chemoprevention," where a patient’s gut microbiome profile could be screened before starting an aspirin regimen. If aspirin-degrading bacteria are present, clinicians might consider:

  • Adjusting the aspirin dosage.
  • Using antibiotics or probiotics to modulate the microbiome.
  • Developing inhibitors to target specific bacterial enzymes responsible for degradation.

Conclusion

The gut microbiota significantly modulates the chemopreventive efficacy of aspirin in mice by reducing its systemic bioavailability. Lysinibacillus sphaericus plays a critical role in this process through aspirin degradation. Future research is needed to translate these findings into human clinical practice, potentially leading to more effective, personalized strategies for colorectal cancer prevention.

Summary updated

Abstract

<h3>Background</h3> The gut microbiota, a pivotal regulator in colorectal cancer (CRC) development, is profoundly involved in drug metabolism. This study aims to decipher the role of the gut microbiota in aspirin-mediated chemoprevention of CRC in mice. <h3>Methods</h3> Two models, azoxymethane (AOM, 10 mg/kg) and dextran sulfate sodium (DSS, 2.0%) induced CRC and APC<sup>min/+</sup> induced CRC, were used in this study. Mice were orally administered aspirin (400 mg/L) with or without periodical antibiotics cocktail (0.1 g/L of vancomycin, 0.2 g/L of ampicillin, metronidazole and neomycin). AOM/DSS-treated germ-free mice and conventionally reared germ-free mice (conventionalized mice) were used for validation. Aspirin concentration was estimated by ultra-high performance liquid chromatography (UHPLC). Aspirin-degrading microbes were identified by UHPLC and16S rRNA gene sequencing. <h3>Results</h3> The tumor number and load were significantly reduced after aspirin treatment in antibiotics-treated mice in both AOM/DSS-treated and APC<sup>min/+</sup> models, but not significantly changed in non-antibiotics-treated mice. Consistently, aspirin-treated germ-free mice exhibited significantly less tumor number and load compared to those not receiving aspirin, which was not seen in conventionalized mice, suggesting that gut microbiota impairs the chemopreventive efficacy of aspirin on CRC. UHPLC analysis revealed that plasma levels of aspirin were significantly higher in microbiota-depleted mice compared to microbiota-intact mice, indicating that gut microbiota limits aspirin bioavailability. Co-incubation of aspirin-containing medium and bacteria showed that aspirin levels in medium were significantly reduced when incubated with the fecal commensal bacteria from microbiota-intact mice compared to those from microbiota-depleted mice. Screening 1,093 bacterial colonies isolated from the feces of microbiota-intact mice revealed that <i>Lysinibacillus sphaericus</i> significantly reduced the aspirin levels in aspirin-containing medium. Moreover, the germ-free mice monocolonized with <i>Lysinibacillus sphaericus</i> showed significantly lower plasma aspirin levels post aspirin administration relative to the intact germ-free mice, confirming a role of this bacterium in reducing aspirin bioavailability. <h3>Conclusions</h3> Gut microbiota modulates the chemopreventive efficacy of aspirin on CRC through impact on aspirin bioavailability in mice. <i>Lysinibacillus sphaericus</i> may play a critical role in aspirin degradation in the gut.
BibTeX
@misc{zhao2019iddf,
  author = {Risheng Zhao and Olabisi Oluwabukola Coker and Jian‐Lin Wu and Liuyang Zhao and Geicho Nakatsu and Xiqing Bian and Joseph J.�Y. Sung and Francis K.L. Chan and Emad El‐Omar},
  title = {{IDDF2019-ABS-0188 Gut microbiota modulates the chemopreventive efficacy of aspirin on colorectal cancer through impact on aspirin bioavailability}},
  year = {2019},
  doi = {10.1136/gutjnl-2019-iddfabstracts.36},
}
Figure